or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    TSM B 1.26 8.73
    MELI A 0.87 6.62
    NVO F -0.01 6.50
    NU C -4.97 4.55
    MNDY A 1.93 3.02
    AZN F 0.38 2.23
    ASML F 0.32 1.11

    Represented by ETF Holdings

    Keywords: Nasdaq 100 E Commerce IBD 50 Inflammation Integrated Circuits Semiconductor Device Fabrication Acid Alternative Payments Anemia Angina Anti Diabetic Drugs Antibodies Argon Asthma Autoimmune And Inflammatory Disease Bank Banking Biopharmaceutical Bipolar Disorder Breast Cancer
    Industries: Banks - Diversified Biotechnology Drug Manufacturers - Major Semiconductor Equipment & Materials Semiconductors Software - Application Specialty Retail

    Recent News for PGIM Jennison International Opportunities ETF & its Holdings

    Date Stock Title
    Nov 2 TSM Nvidia Rides AI Wave To Replace Intel On Dow Jones Industrial Average, Ending Its 25-Year Run
    Nov 1 MELI As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
    Nov 1 NVO Election Day, Fed decision, earnings: What to Watch Next Week
    Nov 1 NVO Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
    Nov 1 ASML Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
    Nov 1 NVO Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Nov 1 ASML What's Going On With Taiwan Semiconductor and ASML Stocks On Friday?
    Nov 1 TSM What's Going On With Taiwan Semiconductor and ASML Stocks On Friday?
    Nov 1 NVO Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
    Nov 1 TSM Taiwan Semiconductor Manufacturing Company Limited (TSM): Among 10 Best Fundamental Stocks to Invest In
    Nov 1 TSM Billionaire Ken Griffin Has Been Quietly Selling Microsoft and Buying This Chip Stock Instead. (Hint: It's not Nvidia.)
    Nov 1 NVO Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
    Nov 1 NVO Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
    Nov 1 NVO Novo Nordisk posts Phase 3 win for obesity drug in MASH
    Nov 1 NVO Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
    Nov 1 NVO Novo, with new results, to seek approval for obesity drug in MASH
    Nov 1 TSM Intel, Samsung Results Rallies Seen Short-Lived on AI Challenges
    Nov 1 ASML 2 Growth Stocks Down 36% and 97% to Buy Right Now
    Nov 1 TSM Meet the Supercharged Growth Stock That Could Join Apple, Nvidia, Microsoft, and Alphabet in the $2 Trillion Club by 2028
    Nov 1 TSM Arm Stock vs. Taiwan Semiconductor Stock: Wall Street Says Buy One and Sell the Other
    Under normal market conditions, the fund invests a majority of its net assets in equity and equity-related securities of non-U.S. companies located in various countries outside the U.S., including non-U.S. issuers located in emerging markets (identified by the subadviser as countries classified by MSCI as emerging and frontier markets). The subadviser uses a combination of fundamental research and systematic portfolio construction. The fund is non-diversified.
    MSCI EAFE Financial Market Morgan Stanley Qualified Institutional Buyer Frontier Markets
    Back to the Main PJIO Page...